Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses
Weina Sun, Yonghong Liu, Fatima Amanat, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 84

Showing 26-50 of 84 citing articles:

SARS-CoV-2 infection induces robust mucosal antibody responses in the upper respiratory tract
Alba Escalera, Amaya Rojo-Fernandez, Alexander Rombauts, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109210-109210
Open Access | Times Cited: 3
The recent advancements in protein nanoparticles for immunotherapy
Miaomiao Xu, Siyuan Wei, Lifan Duan, et al.
Nanoscale (2024) Vol. 16, Iss. 25, pp. 11825-11848
Closed Access | Times Cited: 3
Beyond COVID-19: the promise of next-generation coronavirus vaccines
Reshma Koolaparambil Mukesh, Claude Kwe Yinda, Vincent J. Munster, et al.
npj Viruses (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 3
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats
Johnstone Tcheou, Ariel Raskin, Gagandeep Singh, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 23
SARS-CoV-2 Virus-like Particles Produced by a Single Recombinant Baculovirus Generate Anti-S Antibody and Protect against Variant Challenge
Edward Sullivan, Po-Yu Sung, Weining Wu, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 914-914
Open Access | Times Cited: 17
A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice
Ryan R. Chaparian, Alfred T. Harding, Cait E. Hamele, et al.
Journal of Virology (2022) Vol. 96, Iss. 15
Open Access | Times Cited: 16
Can the Nasal Cavity Help Tackle COVID-19?
Bissera Pilicheva, Radka Boyuklieva
Pharmaceutics (2021) Vol. 13, Iss. 10, pp. 1612-1612
Open Access | Times Cited: 22
A highly efficacious live attenuated mumps virus–based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike
Yuexiu Zhang, Mijia Lu, Mahesh KC, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 33
Open Access | Times Cited: 15
Fate and Transport of Coronavirus Surrogate through Compacted Clays for Pathogenic Waste Disposal
Himanshu Yadav, Tadikonda Venkata Bharat, Shubham Gaurav, et al.
Langmuir (2023) Vol. 39, Iss. 23, pp. 8042-8054
Closed Access | Times Cited: 8
Development of a quantitative ELISA for SARS-CoV-2 vaccine candidate, NDV-HXP-S, with CpG 1018® adjuvant
Marcus Estrada, Changcheng Zhu, Anan Bzami, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 2
Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design Platform
Jingen Zhu, Pan Tao, Ashok K. Chopra, et al.
Annual Review of Virology (2024) Vol. 11, Iss. 1, pp. 395-420
Closed Access | Times Cited: 2
Utilization of Viral Vector Vaccines in Preparing for Future Pandemics
Kimberly A. Hofmeyer, Katherine M. Bianchi, Daniel Wolfe
Vaccines (2022) Vol. 10, Iss. 3, pp. 436-436
Open Access | Times Cited: 13
Advantages and challenges of Newcastle disease virus as a vector for respiratory mucosal vaccines
Rik L. de Swart, George A. Belov
Current Opinion in Virology (2023) Vol. 62, pp. 101348-101348
Closed Access | Times Cited: 7
Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity
Ursino Pacheco-García, Jeanet Serafín‐López
Vaccines (2023) Vol. 11, Iss. 3, pp. 655-655
Open Access | Times Cited: 6
VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern
Kyle L. O’Donnell, Tylisha Gourdine, Paige Fletcher, et al.
Vaccines (2022) Vol. 10, Iss. 3, pp. 435-435
Open Access | Times Cited: 10
Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization
Qiu‐Yan Zhang, Hongqing Zhang, Yanan Zhang, et al.
Antiviral Research (2023) Vol. 220, pp. 105757-105757
Closed Access | Times Cited: 5
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
Miguel Ángel Muñoz-Alía, Rebecca A. Nace, Baskar Balakrishnan, et al.
mBio (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 1
Use of live attenuated recombinant Newcastle disease virus carrying avian paramyxovirus 2 HN and F protein genes to enhance immune responses against species A rotavirus VP6 protein
Rofaida Mostafa Soliman, Keisuke Nishioka, Fumi Murakoshi, et al.
Veterinary Research (2024) Vol. 55, Iss. 1
Open Access | Times Cited: 1
A Phase II Study Integrating a Single-Blind Safety Phase with a Double-Blind, Placebo-Controlled Randomized Phase, Assessing Single-Dose Intramuscular or Intranasal Administration to Evaluate the Safety and Immunogenicity of the Recombinant Vaccine Against COVID-19 (AVX/COVID-12 “Patria”) Based on an Active Newcastle Disease Viral Vector as a Heterologous Booster in Subjects with Evidence of Previous Immunity to SARS-CoV-2
Constantino López‐Macías, Martha Torres, Brenda Armenta-Copca, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Phase II/III Double-Blind Study Evaluating Safety and Immunogenicity of a Single Intramuscular Booster Dose of the Recombinant SARS-CoV-2 Vaccine “Patria” (AVX/COVID-12) Using an Active Newcastle Disease Viral Vector (NDV) during the Omicron Outbreak in Healthy Adults with Elevated Baseline Antibody Titers from Prior COVID-19 and/or SARS-CoV-2 Vaccination
Constantino López‐Macías, Martha Torres, Brenda Armenta-Copca, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Measles Virus-Based Vaccine Expressing Membrane-Anchored Spike of SARS-CoV-2 Inducing Efficacious Systemic and Mucosal Humoral Immunity in Hamsters
Zhihui Yang, Yanli Song, Jie Pei, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 559-559
Open Access | Times Cited: 1
Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals
Alejandro Torres-Flores, Luis Ontiveros‐Padilla, Ruth L. Madera-Sandoval, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Negative-Strand RNA Virus-Vectored Vaccines
Magdalena Murr, Thomas C. Mettenleiter
Methods in molecular biology (2024), pp. 51-87
Closed Access | Times Cited: 1
Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS‐CoV‐2 neutralization
Veronica Aparecida de Lima, João Paulo Silva Nunes, Daniela Santoro Rosa, et al.
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 7
Open Access | Times Cited: 1
Development of multidose thermotolerant formulations of a vector-based Covid-19 vaccine candidate, NDV-HXP-S in different product formats: Stability and preservative efficacy study
Anan Bzami, Changcheng Zhu, Marcus Estrada, et al.
Vaccine X (2024) Vol. 20, pp. 100535-100535
Open Access | Times Cited: 1

Scroll to top